CCND1 and plasma cell myeloma: Furthermore, we employed the murine BCL1 lymphoma model as a model for B cell malignancies with paraprotein secretion and clinical trials in myeloma patients are needed to confirm the tolerability and efficacy of the novel vaccine in humans.